253 related articles for article (PubMed ID: 10897048)
21. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
22. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma.
Accorsi R; Morowitz MJ; Charron M; Maris JM
Pediatr Radiol; 2003 Oct; 33(10):688-92. PubMed ID: 12908090
[TBL] [Abstract][Full Text] [Related]
23. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
25. Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.
Vaidyanathan G; Affleck DJ; Alston KL; Welsh P; Zalutsky MR
Nucl Med Commun; 2004 Sep; 25(9):947-55. PubMed ID: 15319601
[TBL] [Abstract][Full Text] [Related]
26. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
[TBL] [Abstract][Full Text] [Related]
27. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
29. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Gaze MN; Mairs RJ; Boyack SM; Wheldon TE; Barrett A
Br J Cancer; 1992 Dec; 66(6):1048-52. PubMed ID: 1457344
[TBL] [Abstract][Full Text] [Related]
30. [Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].
Sudbrock F; Eschner W; Schmidt M; Simon T; Hero B; Schicha H
Nuklearmedizin; 2006; 45(6):254-61. PubMed ID: 17149494
[TBL] [Abstract][Full Text] [Related]
31. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.
Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG
Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553
[TBL] [Abstract][Full Text] [Related]
32. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines.
Meco D; Lasorella A; Riccardi A; Servidei T; Mastrangelo R; Riccardi R
Eur J Cancer; 1999 Aug; 35(8):1227-34. PubMed ID: 10615234
[TBL] [Abstract][Full Text] [Related]
33. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for
Seo Y; Huh Y; Huang SY; Hernandez-Pampaloni JM; Hawkins RA; Gustafson WC; Vo KT; Matthay KK
Med Phys; 2019 May; 46(5):2477-2486. PubMed ID: 30761545
[TBL] [Abstract][Full Text] [Related]
34. SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted into nude mice.
Clerc J; Halpern S; Fourré C; Omri F; Briançon C; Jeusset J; Fragu P
J Nucl Med; 1993 Sep; 34(9):1565-70. PubMed ID: 8355077
[TBL] [Abstract][Full Text] [Related]
35. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic use of I-131-MIBG in nude mice hosting human neuroblastoma xenografts.
Senekowitsch R; Laubenbacher C; Möllenstädt S; Kriegel H; Pabst HW
Strahlenther Onkol; 1989 Jul; 165(7):566-8. PubMed ID: 2749502
[No Abstract] [Full Text] [Related]
37. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
39. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
Gaze MN; Gains JE; Walker C; Bomanji JB
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
[TBL] [Abstract][Full Text] [Related]
40. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.
Lashford LS; Moyes J; Ott R; Fielding S; Babich J; Mellors S; Gordon I; Evans K; Kemshead JT
Eur J Nucl Med; 1988; 13(11):574-7. PubMed ID: 3350034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]